{
    "nct_id": "NCT04551950",
    "official_title": "Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)",
    "inclusion_criteria": "* Inclusion Criteria for participants enrolling into Cohort 1:\n* Study participants had documented persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix\n* Study participants had not been treated with systemic chemotherapy and were not amenable to curative treatment\n* Prior radiation with or without radio-sensitizing chemotherapy was allowed\n* Inclusion Criteria for participants enrolling into Cohort 2:\n* Participants had documented evidence of cervical adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma International Federation of Gynecology and Obstetrics (FIGO) 2018 Stages 1B2 to 4A\n* Participants had not received prior chemotherapy or radiotherapy for cervical cancer\n* Inclusion Criteria for all participants:\n* Archival tumor tissue sample or newly obtained core or excisional biopsy was required\n* Participants who had Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 to 1 were eligible\n* Participants had a life expectancy greater than or equal to 12 weeks\n* Participants had adequate hematological, hepatic, renal, and coagulation function as defined in the protocol\n* Participants with known Human immunodeficiency virus (HIV) infections were eligible if the criteria described in the protocol were met\n* Participants with Hepatitis B virus (HBV) and/or Hepatitis C virus (HCV) infections were eligible if the criteria described in the protocol were met\n* Other protocol defined inclusion criteria could apply\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Exclusion Criteria for All Participants were:\n* Participants with active central nervous system (CNS) metastases causing clinical symptoms or metastases that required therapeutic intervention were excluded. Participants with a history of treated CNS metastases (by surgery or radiation therapy) were not eligible unless they had fully recovered from treatment, demonstrated no progression for at least 4 weeks, and were not using steroids for at least 7 days prior to the start of study intervention\n* Participants that received any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that did not require immuno-suppression\n* Participants with significant acute or chronic infections\n* Participants with active autoimmune disease that might have deteriorated when receiving an immuno-stimulatory agent\n* Participants with clinically significant cardiovascular/cerebrovascular disease including: a cerebral vascular accident/stroke, myocardial infarction, unstable angina, congestive heart failure, or serious cardiac arrhythmia\n* Participants with a history of bleeding diathesis or recent major bleeding events\n* Participant that had received prior cancer treatment with any other immunotherapy or checkpoint inhibitors or any other immune-modulating monoclonal antibody (mAb)\n* Exclusion Criteria for Participants in Cohort 1A related to use of bevacizumab were:\n* Participants with inadequately controlled hypertension\n* Prior history of hypertensive crisis or hypertensive encephalopathy\n* Participants with significant vascular disease within 6 months prior to Screening\n* Participants with a history of hemoptysis within 1 month prior to Screening\n* Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes\n* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to the first dose of bevacizumab\n* Participants with a history of abdominal or trache-oesophageal fistula or gastrointestinal (GI) perforation within 6 months prior to Screening\n* Participants with clinical signs of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding\n* Participants with evidence of abdominal free air not explained by paracentesis or recent surgical procedure\n* Participants with serious, non-healing wound, active ulcer, or untreated bone fracture\n* Participants with proteinuria\n* Other protocol defined exclusion criteria could apply",
    "miscellaneous_criteria": ""
}